insights_auto
Why is FARN up 2,05%?
Dive Deeperchevron_right
FARN:LON
Faron Pharmaceuticals Oy
GBX 37,25
arrow_upward
+2,05%(+0,75) 1D
2 Okt., 16:30:00 GMT+1 · GBX
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for FARN...
Open
GBX 38,00
High
GBX 38,00
Low
GBX 35,09
Mkt. cap
73,90 m
Avg. vol.
51,36 k
Volume
35,95 k
52-wk high
GBX 193,58
52-wk low
GBX 34,00
EPS
-GBX 0,10
Shares outstanding
31,03 m
No. of employees
36
Open
GBX 38,00
High
GBX 38,00
Low
GBX 35,09
Mkt. cap
73,90 m
Avg. vol.
51,36 k
Volume
35,95 k
52-wk high
GBX 193,58
52-wk low
GBX 34,00
EPS
-GBX 0,10
Shares outstanding
31,03 m
No. of employees
36
News stories
From web sources and news partners
Yahoo! Finance Canada
·
1 minuut gelede
NTHI,TRIN,EFOR,HERZ,FFIN,GO,AVBC,NXRT,CULP,BLCO,VSNT,VIRC,KWY,ENTX,BLIN,GRNT,SSP,GAIA,AFCG,NRGV,APCX,KLTR,THRY,BETR | Stock Prices | Quote Comparison
Simply Wall Street
·
41 minute gelede
Here's Why We're Not At All Concerned With Shattuck Labs' (NASDAQ:STTK) Cash Burn Situation
Seeking Alpha
·
1 uur gelede
My Biggest Warning For Anyone Who Owns The S&P 500 (NYSEARCA:SPY)
The Motley Fool
·
3 uur gelede
The S&P 500 Hasn't Looked This Cheap Based on a Popular Metric in Decades. Should You Buy Stocks Now?
Profile
Faron Pharmaceuticals is a Finnish drug discovery and development company based in Turku, Finland.
The company was founded in 2003 by a group led by Markku Jalkanen, who now acts as the company's Chief Executive Officer. It specialises in the development of treatments for acute organ traumas, vascular damage and cancer immunotherapy.
Its lead product Traumakine has been developed to treat acute respiratory distress syndrome. It is currently undergoing international phase III clinical trials after an open-label, early-phase trial showed promising results in the treatment patients with ARDS. The drug is known to function by enhancing lung CD73 expression and increasing production of anti-inflammatory adenosine, such that vascular leaking and escalation of inflammation are reduced. The U.S. Food and Drug Administration FDA has accepted the proposed protocol design for the next Traumakine study in March 2020. The phase III study is a comparison of efficacy in the treatment of patients with ARDS.
In 2020 Traumakine was selected to take part in the WHO Solidarity trial and REMAP-CAP trials to find drugs for the symptoms of Covid_19. Wikipedia
About Faron Pharmaceuticals Oy